News

The trial, called Oracle MS will evaluate the safety and efficacy of two dosage regimens of cladribine tablets versus placebo in the treatment of patients who have experienced

The combination of this gene with Amsterdam Molecular Therapeutics’s (AMT) proprietary adeno-associated virus gene therapy platform could potentially allow the development of an effective, long-term treatment for this

Both Novo Nordisk and BioGeneriX are existing collaborative partners of Neose. Certain intellectual property rights, including those related to producing glycolipids, have been retained by Neose for future

Karin Hamberg, who is currently executive vice president of drug delivery research and alliance & project management, will assume responsibility for clinical, regulatory, and medical affairs undertaking Dr

The new results from the Crystel study show that after taking Enbrel for a year, either as continuous or intermittent therapy, patients experienced significant skin clearance as well

Mr Lechleiter, president and CEO of Lilly, will succeed outgoing chairman Sidney Taurel, who had previously announced his retirement from the company and the board, effective December 31,

The primary endpoint of the trial was the percentage of participants achieving at least a 75% reduction in psoriasis at week 12 as measured by the Psoriasis Area

In relapsing-remitting multiple sclerosis patients who switched from placebo to laquinimod, 52% reduction in the mean number of GdE lesions was observed (p

This Phase IIb spasticity trial is evaluating the safety, tolerability and efficacy of AV650 in multiple sclerosis (MS) patients at doses up to 900mg/day for one month followed